How did IKT's revenue trends shift in Q4 2024?

Inhibikase Therapeutics Inc. (IKT) experienced a notable shift in its revenue trends during Q4 2024, reflecting strategic focus and operational changes within the company. 1. **Total Revenue Growth**: IKT reported a total revenue of $4.3 million for Q4 2024, marking a 2.1% increase from the $4.2 million recorded in Q4 2023. This uptick indicates a positive trajectory in the company's revenue generation, despite the modest growth rate. 2. **SaaS Revenue Expansion**: The company's Software as a Service (SaaS) revenue surged by 11.8%, reaching $1.5 million in Q4 2024, up from $1.3 million in the corresponding quarter of the previous year. This significant increase suggests that IKT's SaaS offerings are gaining traction and contributing substantially to the revenue base. 3. **Professional Services Revenue Stability**: In contrast to the SaaS segment, Professional Services revenue remained flat at $2.2 million, mirroring the figures from Q4 2023. This stability implies that while the company is seeing growth in other areas, the Professional Services segment may be experiencing some challenges or is yet to fully capitalize on its potential. 4. **Gross Margin Improvement**: IKT achieved a consolidated gross margin of 65.8% in Q4 2024, up from 64.9% in Q4 2023. This improvement suggests a better revenue mix and potential price increases, which are positive indicators for the company's profitability and operational efficiency. Overall, IKT's revenue trends in Q4 2024 reflect a company that is growing in certain areas, such as SaaS, while maintaining stability in others, like Professional Services. The improvements in gross margin and total revenue, despite the modest increase, point to a company that is moving in a positive direction financially.